BTK and B-cell chronic lymphocytic leukemia: Clinical observations indicate that patients with CLL and Waldenström macroglobulinemia treated with ibrutinib exhibit only mild symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, suggesting that BTK inhibition may mitigate the inflammatory damage caused by the virus (23).